AstraZeneca and Eli Lilly have announced they are expanding their unprecedented partnership to defeat dementia.
The pharmaceutical giants are collaborating to develop an Alzheimer’s drug. MEDI1814 would selectively bind to amyloid-beta 42, which is associated with Alzheimer’s disease, to potentially slow the disease’s progression.
“MEDI1814 has a unique mechanism among antibodies in clinical development and could provide a distinct approach to treating Alzheimer’s disease,” said Mene Pangalos, AztraZeneca executive vice president of IMED biotech unit and business development to Pharmacy Times.
The drug is currently in phase 1 trials and builds upon an existing collaboration linked to AZD3293, a BACE inhibitor that is currently in two phase 3 trials.
Get the latest information and other valuable topics at this two-day forum bringing together administrators, policy advocates, educators, researchers, gerontologists, and clinical professionals working to improve quality of care and lifestyle, operational efficiency, and resident safety and satisfaction for seniors and the professionals who care for them.